Categories

AstraZeneca shares the latest overall survival (OS) data for IMFINZI® in combination with IMJUDO®

AstraZeneca recently shared the latest overall survival (OS) data for IMFINZI® (durvalumab) in combination with IMJUDO®(tremelimumab-actl) for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).1,2  Primary AnalysisThe primary analysis demonstrated statistically significant improvement in the primary endpoint of OS vs sorafenib in the first-line (1L) treatment of uHCC1,2: *The HR is based on the stratified Cox proportional hazards […]

Read More No Comments

Takeda Provides Update on EXKIVITY® (mobocertinib)

Takeda has announced that following discussions with the U.S. Food and Drug Administration (FDA), we will begin the process of voluntarily withdrawing EXKIVITY (mobocertinib) from the U.S. market over the next few months. EXKIVITY is currently indicated for adult patients with epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive (insertion+) locally advanced or metastatic non-small […]

Read More No Comments

New Data for TAGRISSO® (osimertinib) in the ADAURA Trial

AstraZeneca recently announced that new data from the ADAURA trial regarding AGRISSO® (osimertinib) has been released. The ADAURA trial is an ongoing study of TAGRISSO as adjuvant therapy after tumor resection in adult patients with completely resected Stage IB-IIIA EGFRm (exon 19 deletions or exon 21 L858R mutations) non-small cell lung cancer (NSCLC). TAGRISSO was approved as […]

Read More No Comments

Register Now for OSCO’s “Best of” San Antonio Breast Cancer Symposium® Virtual Symposium to be held March 19, 2022

The Oklahoma Society of Clinical Oncology, Inc. would like to invite you to attend our 2022 Spring meeting. Join your colleagues to hear highlights from this state-of-the art symposium on the experimental biology, etiology, prevention, diagnosis and therapy of breast cancer and premalignant breast disease. The “Best of” SABCS is an officially licensed program of the San Antonio […]

Read More No Comments

Novartis announces new treatment approval for SCEMBLIX®

Novartis is pleased to announce that SCEMBLIX® (asciminib) tablets is now approved for the treatment of adult patients with: ·  Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with 2 or more tyrosine kinase inhibitors (TKIs) ○     This indication is approved under accelerated approval based on major molecular response (MMR). Continued approval […]

Read More No Comments

Oncopeptides withdraws Pepaxto® in US, scale down organization and focus on R&D

October 22, 2021     Subject: Voluntary withdrawal of PEPAXTO® (melphalan flufenamide) for the treatment of relapsed or refractory multiple myeloma   Dear Healthcare Provider:  This letter is to inform you about important information regarding PEPAXTO in the United States.  On October 22, 2021, Oncopeptides announced the decision to voluntarily withdraw the US accelerated approval for […]

Read More No Comments

New life-changing survival data for women with HR+/HER2- metastatic breast cancer

Novartis is pleased to share new study results for KISQALI® (ribociclib), which now include overall survival (OS) data that no other CDK 4/6 inhibitor has yet reported: statistically significant OS in in first-line postmenopausal patients with an aromatase inhibitor.1 MONALEESA-2 was a dedicated first-line trial of KISQALI + letrozole vs placebo + letrozole in postmenopausal patients […]

Read More No Comments

Natera’s Signatera® Selected for US Trial

Natera is proud to announce that Signatera has been selected for NRG Oncology pivotal CIRCULATE – US trial for patients with resected stage II or III colon cancer. CIRCULATE -US (NRG-G1008) is a prospective, multi-center, randomized clinical trial that aims to establish a new standard of care (SOC) for these patients using Signatera MRD to guide […]

Read More No Comments

OSCO and ASCO Supported Co-Pay Accumulator Ban Bill Signed into Law

On April 19, Oklahoma Governor Kevin Stitt (R) signed co-pay accumulator ban bill HB 2678 into law. This measure requires Pharmacy Benefit Managers (PBMs) to include any amount paid by an enrollee, or on behalf of an enrollee, when calculating the enrollee’s out of pocket maximum, copay, coinsurance, deductible, or cost sharing requirement. The Oklahoma […]

Read More No Comments

Merck provides support for patients affected by COVID-19 pandemic

During this unprecedented time, Merck is committed to ensuring their medicines and vaccines reach their patients and customers. This includes supporting patients who might need more help today with their medications, including those who are unemployed or have lost insurance coverage due to the COVID-19 pandemic. To learn about what support options may be available, […]

Read More No Comments